Metastatic Prostate Cancer Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Metastatic Prostate Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “Metastatic Prostate Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of metastatic prostate cancer. It projects the future incidence and prevalence rates of metastatic prostate cancer cases across various populations. The study covers age, gender, and type as major determinants of the metastatic prostate cancer population. The report highlights patterns in the prevalence of metastatic prostate cancer over time and projects future trends based on multiple variables.

Metastatic Prostate Cancer Understanding: Disease Overview

Metastatic prostate cancer represents the advanced stage of prostate malignancy, occurring when cancer spreads beyond the prostate to bones, lymph nodes, or visceral organs. It includes hormone-sensitive and castration-resistant forms, each with distinct biological behavior and treatment strategies. Symptoms include bone pain, fatigue, and urinary complications. Fueled by aging demographics and improved imaging technologies, detection rates have risen globally. Despite therapeutic advancements, metastatic disease remains associated with significant morbidity and mortality, underscoring the need for earlier diagnosis, optimized systemic therapies, and enhanced management of treatment resistance.

Metastatic Prostate Cancer Epidemiology Perspective

The metastatic prostate cancer epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the metastatic prostate cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for metastatic prostate cancer and their trends. The metastatic prostate cancer detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Globally, prostate cancer is the fourth most prevalent cancer, and among men, it remains the second most commonly diagnosed cancer, reflecting its significant worldwide burden.
• Bone metastasis is a hallmark of advanced prostate cancer and a leading cause of morbidity (pain, fractures, spinal cord compression).
• Men especially from West African and Caribbean descent have the highest incidence and mortality rates globally, reflecting both genetic predisposition and healthcare access inequities.
• Approximately 10 million men globally are diagnosed with prostate cancer, of which ≈700,000 cases are metastatic.
• In 2022, 1.5 million new prostate cancer cases were reported, representing 7.3% of all cancers, with 397,000 deaths (mortality rate 7.3%).

Read more about this report - Request a Free Sample

Country-wise Metastatic Prostate Cancer Epidemiology Segment

The metastatic prostate cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, prostate cancer remains the most diagnosed cancer in men and the second leading cause of cancer-related deaths. About 12.9% of men will develop the disease, with most diagnoses occurring between 65–74 years and a median age of 68 years. A 2023 analysis estimated 120,400 U.S. men living with metastatic prostate cancer, with 45% presenting with de novo metastases. Earlier detection through PSA screening continues to shape diagnostic patterns. Overall, these insights highlight the importance of enhanced metastatic care strategies.

Metastatic Prostate Cancer: Treatment Overview

Treatment of metastatic prostate cancer centers on androgen deprivation therapy, often combined with next-generation hormonal agents such as abiraterone, enzalutamide, or apalutamide. Chemotherapy with docetaxel or cabazitaxel benefits selected patients, while bone-targeted agents address skeletal complications. Radioligand therapies, including PSMA-targeted treatments, are expanding therapeutic options. For metastatic castration-resistant disease, sequencing strategies and biomarker-guided approaches are increasingly important. Integration of targeted agents, improved imaging, and combination regimens is enhancing survival and quality of life, reflecting rapid innovation within prostate oncology.

Key Questions Answered

• What are the key findings of metastatic prostate cancer epidemiology in the 8 major markets?
• What will be the total number of patients with metastatic prostate cancer across the 8 major markets during the forecast period?
• What was the country-wise metastatic prostate cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of metastatic prostate cancer during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of metastatic prostate cancer during the forecast period of 2026-2035?
• What are the currently available treatments for metastatic prostate cancer?
• What are the disease risks, signs, symptoms, and unmet needs of metastatic prostate cancer?

Scope of the Metastatic Prostate Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of metastatic prostate cancer based on several factors.
• Metastatic Prostate Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The metastatic prostate cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Metastatic Prostate Cancer Market

Metastatic Prostate Cancer Drug Pipeline Analysis